Amneal Pharmaceuticals (NYSE: AMRX) closes Kashiv deal with $375M cash and new stock

Rhea-AI Filing Summary

Amneal Pharmaceuticals, Inc. completed the acquisition of Kashiv BioSciences, LLC, purchasing 100% of Kashiv’s membership interests through its wholly owned subsidiary Amneal Pharmaceuticals LLC. The consideration at closing included $375,000,000 in cash, subject to purchase price adjustments, and the issuance of 28,942,098 shares of Class A common stock as stock consideration to the sellers.

Under the purchase agreement, the sellers may receive up to an additional $350,000,000 in contingent payments tied to specified U.S. regulatory milestones for up to six Kashiv product candidates, plus potential contingent royalty payments over 12 years equal to 25% of certain annual gross profits above defined hurdles. To help fund the transaction, Amneal LLC entered into an amendment to its term loan credit agreement, under which Bank of America, N.A. provided a $350,000,000 incremental term loan.

Amneal amended its Stockholders Agreement to ensure the new stock consideration is counted in Amneal Group ownership calculations and relied on a private-offering exemption to issue the shares to accredited investors. The company plans to file an S-3 registration statement to permit public resale of the stock consideration and will later provide Kashiv’s financial statements and pro forma financial information.

Filing Explained

Integration is underway, while issued stock awaits resale registration and 350 million dollars of new term-loan principal funded part of the consideration.

The August 10, 2026 Form 8-K reports that Amneal completed the Kashiv acquisition, while the stock consideration issued at closing remains unregistered; the company committed to file an S-3 for public resale by the later of 30 days after closing or 10 business days after receiving required seller information.

An S-3 is a shelf registration that creates capacity for future registered sales; filing it does not itself sell shares. Here, the filing describes registration for the sellers’ resale of the issued stock, not another issuance by Amneal.

Although the press-release exhibit calls the combination a “fully integrated” biosimilars leader, the filing says integration planning and related activities are underway, placing operational integration at a planning stage rather than reporting its completion.

The $350 million incremental term loan increased the outstanding principal of prior term loans, and its proceeds funded part of the acquisition consideration.

Amneal’s specified follow-up is an amendment filing with Kashiv’s financial statements and acquisition pro forma information no later than 71 calendar days after this report’s filing deadline.

8-K Event Classification

6 items: 1.01, 2.01, 2.03, 3.02, 7.01, 9.01

6 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 2.01 Completion of Acquisition or Disposition of Assets Financial

The company completed a significant acquisition or sale of business assets.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial

The company incurred a new significant debt or off-balance-sheet obligation.

Item 3.02 Unregistered Sales of Equity Securities Securities

The company sold equity securities in a private placement or other unregistered transaction.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Cash consideration: $375,000,000 Stock consideration: 28,942,098 shares Regulatory milestone contingent payments: Up to $350,000,000 +3 more

6 metrics

Cash consideration $375,000,000 Cash paid at closing for the acquisition, subject to purchase price adjustments

Stock consideration 28,942,098 shares Class A common stock issued to Kashiv sellers at closing

Regulatory milestone contingent payments Up to $350,000,000 Potential additional consideration upon achievement of specified U.S. regulatory milestones

Contingent royalty rate 25% Royalty on certain annual aggregate gross profits above specified hurdles for designated products

Royalty period 12 years Duration following closing during which contingent royalty payments may be earned

Incremental Term Loan $350,000,000 New Incremental Term Loan provided under Amendment No. 4 to Term Loan Credit Agreement

Key Terms

Membership Interest Purchase Agreement, Stock Consideration, Incremental Term Loan, contingent royalty payments, +1 more

5 terms

Membership Interest Purchase Agreement regulatory

"the previously announced Membership Interest Purchase Agreement, dated as of April 21, 2026"

A membership interest purchase agreement is a contract used when someone buys an ownership stake in a limited liability company (LLC). It spells out what is being sold, the price, any promises about the business’s condition, and who takes responsibility for debts or legal issues—like a receipt and rulebook for the sale. Investors care because it transfers control, affects future cash flow and liabilities, and can change the value and tax treatment of their investment.

Stock Consideration financial

"28,942,098 shares of its Class A Common Stock ... the “Stock Consideration”"

Stock consideration is when a company pays for an acquisition, merger, or other corporate deal by issuing its own shares instead of using cash. It matters to investors because receiving or issuing stock changes who owns what: sellers get a stake in the combined business and existing shareholders see their piece of the company shrink, similar to adding more slices to a pie. That shift affects potential returns, voting control, and future share value.

Incremental Term Loan financial

"Bank of America, N.A. made an Incremental Term Loan ... in an aggregate principal amount of $350,000,000"

An incremental term loan is an additional lump-sum loan that a borrower adds onto an existing long-term loan package, usually under the same agreement but with new funds and repayment terms. For investors, it matters because this extra borrowing changes a company’s debt load and interest obligations—like adding a room to a house and increasing the mortgage—potentially affecting credit risk, cash available for dividends, and the value of existing shares or bonds.

contingent royalty payments financial

"eligible to receive certain potential contingent royalty payments equal to 25% of the amount by which annual aggregate gross profits"

accredited investors regulatory

"The Sellers represented to Amneal that they are “accredited investors” as defined in Rule 501 of the Securities Act"

Accredited investors are individuals or entities considered to have enough financial knowledge and resources to understand and handle more complex and risky investments. They are often allowed to participate in private investment opportunities that are not available to the general public, similar to how experienced players might access exclusive clubs or events. This status helps ensure that investors can manage potential risks and rewards appropriately.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 08/10/2026 - 04:06 PM Accepted by SEC EDGAR 08/10/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What did Amneal Pharmaceuticals (AMRX) acquire in this 8-K transaction?

Amneal acquired 100% of the membership interests of Kashiv BioSciences, LLC through its subsidiary Amneal Pharmaceuticals LLC, creating an integrated biosimilars platform spanning research, development, manufacturing, and commercialization.

How much did Amneal (AMRX) pay to acquire Kashiv BioSciences?

At closing, Amneal paid $375,000,000 in cash, subject to purchase price adjustments, and issued 28,942,098 Class A shares as stock consideration to the Kashiv sellers.

What contingent payments are tied to the Amneal (AMRX) and Kashiv deal?

The sellers may receive up to $350,000,000 in additional contingent payments based on achieving specified U.S. regulatory milestones for up to six Kashiv product candidates, plus potential royalty payments over 12 years based on certain gross profit thresholds.

How is Amneal (AMRX) financing the Kashiv acquisition?

Amneal LLC obtained a $350,000,000 Incremental Term Loan under an amendment to its Term Loan Credit Agreement, with proceeds used as part of the cash consideration for the Kashiv acquisition.

How were the new Amneal (AMRX) shares for the Kashiv acquisition issued?

Amneal issued 28,942,098 Class A shares as stock consideration in a private transaction relying on the Section 4(a)(2) Securities Act exemption, with sellers representing they are accredited investors acquiring the securities for investment.

Will Amneal (AMRX) register the new shares issued in the Kashiv deal?

Amneal agreed to file a Form S-3 registration statement to permit public resale of the stock consideration, by a date tied to 30 days after closing or 10 business days after receiving required information from the sellers.

What additional financial disclosures will Amneal (AMRX) provide about the Kashiv acquisition?

Amneal plans to file Kashiv’s financial statements and related pro forma financial information by amendment to this report, no later than 71 days after the required filing date.

false000172312800017231282026-08-102026-08-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 10, 2026

AMNEAL PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38485		93-4225266
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

400 Crossing Blvd

Bridgewater, NJ 08807

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (908) 947-3120

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, par value $0.01 per share		AMRX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Introductory Note

This Current Report on Form 8-K (this “Report”) is being filed in connection with the completion of the transactions contemplated by the previously announced Membership Interest Purchase Agreement, dated as of April 21, 2026 (as it may be amended from time to time, the “Purchase Agreement”), by and among Amneal Pharmaceuticals, Inc., a Delaware corporation (“Amneal”), Kashiv BioSciences, LLC (“Kashiv”), KB Seller Representative, LLC (the “Seller Representative”) and the equityholders of Kashiv named therein (the “Sellers”). On August 10, 2026 (the “Closing Date”), pursuant to the Purchase Agreement, Amneal Pharmaceuticals LLC, a Delaware limited liability company and wholly owned subsidiary of Amneal (“Amneal LLC”), acting pursuant to the terms and conditions of a previously executed assignment and assumption agreement between it, Amneal, Kashiv and the Seller Representative, purchased from the Sellers, and the Sellers sold, conveyed, assigned, transferred and delivered to Amneal LLC, 100% of the issued and outstanding membership interests of Kashiv (the “Acquisition”). Pursuant to the Purchase Agreement, at the closing of the Acquisition (the “Closing”), (i) Amneal LLC was required to pay to the Sellers $375,000,000 in cash, subject to certain purchase price adjustments including for cash, the funding of operations between signing and closing (subject to a specified cap, calculated on the basis of the period from the date of the Purchase Agreement until the Closing), indebtedness, transaction expenses and working capital fluctuations (relative to a target), and (ii) Amneal was required to issue to the Sellers 28,942,108 shares of its Class A common stock, par value $0.01 per share, subject to adjustments for fractional shares. The Sellers will also be eligible to receive up to an additional $350,000,000 in potential contingent payments upon the achievement of certain regulatory milestones in the United States for up to six designated Kashiv product candidates. In addition, during the 12-year period following the Closing, the Sellers will be eligible to receive certain potential contingent royalty payments equal to 25% of the amount by which annual aggregate gross profits for certain products exceed specified gross profit hurdle amounts for the corresponding annual royalty period.

As previously reported, certain of the Sellers are affiliates of the Amneal Group (as defined in Amneal’s proxy statement for its 2026 annual meeting of stockholders, which was filed with the Securities and Exchange Commission (the “SEC”) on March 25, 2026).

The foregoing description of the Purchase Agreement and the Acquisition do not purport to be complete and are qualified in their entirety by reference to the full text of the Purchase Agreement, a copy of which was filed as Exhibit 2.1 to the Current Report on Form 8-K filed by Amneal on April 22, 2026 and is incorporated herein by reference.

Item 1.01 Entry into a Material Definitive Agreement.

The information set forth under the Introductory Note of this Report is incorporated into this Item 1.01 by reference.

First Amendment to the Third Amended and Restated Stockholders Agreement  

In connection with the consummation of the Acquisition, on the Closing Date, Amneal entered into a First Amendment to the Third Amended and Restated Stockholders Agreement (the “Stockholders Agreement Amendment”) with Vikram Patel, in his capacity as the Amneal Group Representative (as defined in the Third Amended and Restated Stockholders Agreement, dated November 7, 2023, by and among Amneal, Amneal Intermediate Inc., Amneal LLC, and the other parties named therein (the “Stockholders Agreement”)), pursuant to which Amneal and the Amneal Group Representative agreed, among other things, to amend the definition of “Amneal Group” and “Amneal Group Member” (in each case, as defined in the Stockholders Agreement), and to clarify that the Stock Consideration (as defined below) issued to the members of the Amneal Group in connection with the Acquisition will be included in the number of shares owned by the Amneal Group for all purposes of the Stockholders Agreement.

The foregoing description of the Stockholders Agreement Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Stockholders Agreement Amendment, which is attached hereto as Exhibit 10.1.

Amendment No. 4 to the Term Loan Credit Agreement

On August 10, 2026, Amneal LLC and certain of Amneal LLC’s subsidiaries, as guarantors, entered into that certain Amendment No. 4 to Term Loan Credit Agreement (the “New Incremental Term Loan Amendment”) with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”), and the other lenders party thereto consenting to the New Incremental Term Loan Amendment. The New Incremental Term Loan Amendment amends certain terms in that certain Term Loan Credit Agreement, dated as of November 14, 2023 (as amended, restated, supplemented or otherwise modified prior to the date hereof, the “Credit Agreement”; the Credit Agreement, as amended by the New Incremental Term Loan Amendment, the “Amended Credit Agreement”), by and among Amneal LLC, certain of Amneal LLC’s subsidiaries party thereto as guarantors, the lenders party thereto and the Agent. Pursuant to the New Incremental Term Loan Amendment, Bank of America, N.A. made an Incremental Term Loan (as defined in the Amended Credit Agreement) (the “New Incremental Term Loan”) to Amneal LLC on the Amendment No. 4 Effective Date (as defined in the New Incremental Term Loan Amendment) in an aggregate principal amount of $350,000,000 in the form of an increase in the aggregate principal amount of outstanding Amendment No. 3 Term Loans (as defined in the Amended Credit Agreement), the proceeds of which were used as a portion of the consideration for the Acquisition.

The foregoing description of the New Incremental Term Loan Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the New Incremental Term Loan Amendment, which is attached hereto as Exhibit 10.2.

Item 2.01 Completion of Acquisition or Disposition of Assets.

The information set forth in the Introductory Note of this Report is incorporated into this Item 2.01 by reference.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth in the Introductory Note and Item 1.01 of this Report is incorporated into this Item 2.03 by reference.

Item 3.02 Unregistered Sales of Equity Securities.

The information set forth in the Introductory Note of this Report is incorporated into this Item 3.02 by reference. Pursuant to the Purchase Agreement, upon the Closing, Amneal issued to the Sellers 28,942,098 shares of its Class A Common Stock, par value $0.01 per share (as adjusted downward for fractional shares pursuant to the Purchase Agreement, the “Stock Consideration”). The issuance of the Stock Consideration to the Sellers was made in reliance upon the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), provided by Section 4(a)(2) thereof as a transaction by an issuer not involving any public offering. The Sellers represented to Amneal that they are “accredited investors” as defined in Rule 501 of the Securities Act and that the securities are being acquired for investment purposes and not with a view to, or for sale in connection with, any distribution thereof. Pursuant to the Purchase Agreement, Amneal has agreed to file with the SEC a registration statement on Form S-3 to provide for the public resale of the Stock Consideration by the later of (i) 30 days following the Closing Date and (ii) 10 business days following the receipt by Amneal of information reasonably required from the Sellers to be included or incorporated by reference in such registration statement.

Item 7.01 Regulation FD Disclosure.

On the Closing Date, Amneal issued a press release announcing the closing of the Acquisition. A copy of the press release is attached as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

(a) Financial statements of businesses or funds acquired.

Amneal intends to file the financial statements of Kashiv required by Item 9.01(a) by amendment to this Report no later than 71 calendar days following the date that this Report is required to be filed.

(b) Pro forma financial information.

Amneal intends to file the pro forma financial information relating to the Acquisition required by Item 9.01(b) by amendment to this Report no later than 71 calendar days following the date of this Report is required to be filed.

(d) Exhibits

Exhibit No.		Description
2.1		Membership Interest Purchase Agreement, dated as of April 21, 2026, by and among Amneal Pharmaceuticals, Inc., Kashiv BioSciences, LLC, KB Seller Representative, LLC and the equityholders of Kashiv named therein (incorporated by reference to Exhibit 2.1 to Amneal’s Current Report on Form 8-K filed on April 22, 2026).
10.1		First Amendment to the Third Amended and Restated Stockholders Agreement by and among Amneal, Amneal Intermediate Inc., Amneal LLC, and the other parties named therein.
10.2		Amendment No. 4 to Term Loan Credit Agreement by and among Amneal LLC, certain of Amneal LLC’s subsidiaries, as guarantors, the Lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent.
99.1		Press release issued August 10, 2026.
104		The cover page from this Report, formatted in iXBRL (Inline eXtensible Business Reporting Language).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 10, 2026	AMNEAL PHARMACEUTICALS, INC.
	By:		/s/ Jason B. Daly
	Name:		Jason B. Daly
	Title:		Executive Vice President, Chief Legal Officer and Corporate Secretary

Exhibit 99.1

Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader

Establishes an integrated global platform spanning biosimilar R&D, manufacturing and commercialization

Adds a major long-term growth pillar and extends Amneal’s growth profile into the 2030s

BRIDGEWATER, N.J., August 10, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the completion of its acquisition of Kashiv BioSciences, LLC (“Kashiv”), creating a fully integrated global biosimilars leader with end-to-end capabilities across research, development, manufacturing and commercialization. The combination establishes one of the industry’s few fully integrated biosimilars platforms.

“The completion of this acquisition marks a pivotal step in Amneal’s strategy to become America’s #1 Affordable Medicines company,” said Chirag Patel, Co-Founder and Co-Chief Executive Officer. “With this acquisition, we have created an integrated biosimilars business that can launch multiple biosimilars each year and extends our growth profile into the next decade.”

“We are pleased to welcome the Kashiv team to Amneal and thank our shareholders and other stakeholders for their strong support,” said Chintu Patel, Co-Founder and Co-Chief Executive Officer. “This acquisition helps to position Amneal to capitalize on an unprecedented wave of biologic loss of exclusivity. Together, we will pursue this significant opportunity and work to expand patient access to high-quality, affordable biologic medicines.”

Strategic Combination

The acquisition combines Kashiv’s biologics research, development and manufacturing capabilities with Amneal’s commercial scale, establishing biosimilars as a major long-term growth pillar within the Company’s Affordable Medicines business. The transaction provides Amneal access to the global biosimilars market with more than $300 billion projected global biologics loss-of-exclusivity over the next decade. The combined portfolio is expected to support a consistent cadence of biosimilar launches for years to come.

Integration and Next Steps

The transaction builds on a relationship between Amneal and Kashiv spanning more than a decade, providing a strong foundation for integration. Integration planning and related activities are underway and are focused on combining the companies’ development and manufacturing capabilities and advancing the biosimilar pipeline.

Goldman Sachs & Co. LLC served as financial advisor and Richards, Layton & Finger, P.A. served as legal counsel to the Committee of Independent Directors of the Board of Directors. Simpson Thacher & Bartlett LLP served as legal counsel, among other financial and compliance advisors, to Amneal.

J.P. Morgan Securities LLC served as financial advisor, Holland & Knight LLP served as legal counsel, and Dhinal Shah Associates served as an advisor in India to Kashiv.

About Amneal

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit amneal.com and follow us on LinkedIn.

About Kashiv BioSciences

Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets and is among the few U.S.-based companies to both manufacture and receive marketing authorization for multiple biosimilars. Kashiv BioSciences, LLC in the U.S., together with its subsidiaries in India (collectively, “Kashiv BioSciences”) operates with robust infrastructure and highly skilled teams that provide global R&D, clinical, manufacturing, regulatory, and IP capabilities. Kashiv BioSciences believes that its people, partners, and shared purpose fuel its work to advance patient care and access to important medicines. For additional information, please visit kashivbiosciences.com and follow Kashiv BioSciences on LinkedIn.

Cautionary Statement on Forward-Looking Statements

Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: our growth profile; our ability to obtain approval for and launch biosimilars and the frequency of such launches; our ability to become America’s #1 Affordable Medicines company; our ability to capitalize on losses of exclusivity; our ability to expand patient access to medicines; our integration prospects; our ability to create value for our shareholders; and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements. 

The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, our integration of research, development, manufacturing and commercialization capabilities, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company.

Such risks and uncertainties include, but are not limited to: our ability to successfully integrate Kashiv; our ability to successfully develop, license, acquire, obtain approval for and commercialize new products on a timely basis; the competition we face in the pharmaceutical and biologics industry from brand and generic product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; the impact of illegal distribution and sale by third parties of counterfeit versions of our products or stolen products; the impact of negative market perceptions of us and the safety and quality of our products; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the continuing trend of consolidation of certain customer groups; the impact of supply chain disruption; the imposition of tariffs may adversely affect our business, results of operations and financial condition; a U.S. government shutdown could adversely impact our regulatory, operational and financial performance; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; our dependence on information technology systems and infrastructure and the potential for cybersecurity incidents, and risks associated with artificial intelligence; the impact of a prolonged business interruption within our supply chain; our ability to attract, hire and retain highly skilled personnel; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of claims brought against us by third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to government contracting, healthcare fraud abuse, most-favored nation pricing policies, government price controls, and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements and review processes; the impact of healthcare reforms and changes in coverage and reimbursement levels and funding by governmental authorities and other third-party payers, including increases in the number of uninsured individuals and the impact of the expiration of enhanced premium tax credits and subsidies for eligible households that enroll in qualified health plans offered in Patient Protection and Affordable Care Act health insurance exchanges; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; our dependence on third-party agreements for a portion of our product offerings; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties; the impact of global economic, political or other catastrophic events; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A common stock by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Investor Contact

Anthony DiMeo

VP, Investor Relations

anthony.dimeo@amneal.com

Media Contact

Brandon Skop

Sr. Director, Corporate Communications

brandon.skop@amneal.com

Filing Exhibits & Attachments

6 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 17.8 KB

Agreements & Contracts

• EX-10.1 EXHIBIT 10.1 79.8 KB
• EX-10.2 EXHIBIT 10.2 64.1 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.8 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 21.5 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 15.7 KB